Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Monday that new preclinical data on the antibody CAN04 is being presented at the 11th annual PEGS (Protein & Antibody Engineering Summit) Europe conference, from 18 November 2019 to 22 November 2019, in Lisbon, Portugal.
The PEGS conference is a key annual conference around novel antibody designs and strategies for development. The poster entitled 'Glycoengineered Murine Antibodies as Surrogates to the Humanised and ADCC-enhanced Anti-IL1RAP Antibody CAN04 (nidanilimab)' is presented by Dr Camilla Rydberg Millrud, and Dr David Liberg.
CAN04 is in clinical development for cancer and is designed to enhance immune-mediated tumour cell killing. Reportedly, these new results show that similar design applied to CAN04 surrogate antibodies enhance antitumour effects in experimental cancer models and further support for the strategy chosen.
Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and blockade of interleukin 1 signalling.
Currently, CAN04 is being investigated in an open label three-armed phase I/IIa clinical trial, CANFOUR. Two arms investigate safety and efficacy of CAN04 in combination with two different first line chemotherapy regimes in patients with non-small cell lung cancer or pancreatic cancer. A third arm investigates safety and biomarkers of CAN04 monotherapy in patients with late stage disease. One additional trial, investigating CAN04 with an immune checkpoint inhibitor is planned to start early 2020.
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Genprex increases sites for Acclaim-3 clinical trial
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib